No Data
No Data
No Data
No Data
No Data
Express News | B of A Securities Reinstates Neutral on Akero Therapeutics, Announces $30 Price Target
Moomoo 24/7Apr 22 06:21 ET
Akero Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 44.51% B of A Securities → $30 Reinstates → Neutral 03/05/2024 102.31% UBS $39 → $42 Maintains
BenzingaApr 22 06:20 ET
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Seeking AlphaApr 19 17:10 ET
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Seeking AlphaApr 9 10:03 ET
Akero Therapeutics(AKRO.US) Officer Sells US$121.91K in Common Stock
$Akero Therapeutics(AKRO.US)$ Officer Young Jonathan sold 5,000 shares of Common Stock on Apr 1, 2024 at an average price of $24.3826 for a total value of $121.91K.Source: Announcement What is stateme
moomoo NewsApr 3 19:37 ET
Ademi LLP Investigates Claims of Securities Fraud Against Akero Therapeutics, Inc.
MILWAUKEE, April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Akero (Nasdaq: AKRO). The investigation results from inaccurate statements Akero may have
PR NewswireApr 2 18:05 ET
No Data
No Data